Pharvaris (NASDAQ:PHVS – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 181,400 shares, a growth of 39.5% from the August 15th total of 130,000 shares. Currently, 1.0% of the company’s stock are sold short. Based on an average trading volume of 78,200 shares, the days-to-cover ratio is presently 2.3 days.
Pharvaris Trading Down 1.5 %
Shares of Pharvaris stock traded down $0.32 during trading hours on Monday, reaching $20.60. The company’s stock had a trading volume of 136,277 shares, compared to its average volume of 85,952. The company’s 50 day simple moving average is $18.14 and its 200 day simple moving average is $20.00. Pharvaris has a one year low of $15.00 and a one year high of $33.00.
Pharvaris (NASDAQ:PHVS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). On average, equities analysts expect that Pharvaris will post -2.58 earnings per share for the current year.
Analyst Ratings Changes
Get Our Latest Analysis on PHVS
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. venBio Partners LLC increased its holdings in shares of Pharvaris by 15.4% in the 4th quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after acquiring an additional 654,832 shares during the period. Novo Holdings A S increased its holdings in shares of Pharvaris by 47.7% in the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock worth $32,430,000 after acquiring an additional 556,970 shares during the period. Deerfield Management Company L.P. Series C increased its holdings in shares of Pharvaris by 31.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock worth $26,269,000 after acquiring an additional 335,687 shares during the period. Commodore Capital LP acquired a new stake in shares of Pharvaris in the 4th quarter worth about $22,440,000. Finally, Sofinnova Investments Inc. increased its holdings in shares of Pharvaris by 2.9% in the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock worth $11,309,000 after acquiring an additional 16,862 shares during the period.
About Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
- Five stocks we like better than Pharvaris
- What is MarketRankā¢? How to Use it
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- 3 Stocks to Consider Buying in October
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What is a Death Cross in Stocks?
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.